Cover Image
市場調查報告書

顯影劑腎臟病:全球臨床實驗趨勢

Contrast Induced Nephropathy Global Clinical Trials Review, H2, 2015

出版商 GlobalData 商品編碼 341580
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
顯影劑腎臟病:全球臨床實驗趨勢 Contrast Induced Nephropathy Global Clinical Trials Review, H2, 2015
出版日期: 2015年09月10日 內容資訊: 英文 74 Pages
簡介

本報告提供顯影劑腎臟病相關臨床研究最新趨勢相關分析、疾病、治療方法概要,及G7及E7各國的臨床實驗狀況、各地區、各階段的進行狀況、有潛力的贊助商、各企業及研究機關的研究進行狀況、有潛力的藥劑比較等資訊彙整,為您概述為以下內容。

簡介

  • 顯影劑腎臟病
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 主要國家的臨床實驗數量; 中東/非洲地區
    • 主要國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量:顯影劑腎臟病臨床實驗數量的尿生殖器及性荷爾蒙系疾病臨床實驗數量比率

各相位臨床實驗數量:G7各國

G7各國的臨床實驗數量:各相位

E7各國的臨床實驗數量:顯影劑腎臟病臨床實驗數量的尿生殖器及性荷爾蒙系疾病臨床實驗數量比率

各相位臨床實驗數量: E7各國

E7各國的臨床實驗數量:各相位

各相位臨床實驗數量

  • 各相位的進展中臨床實驗數量

各進展狀況臨床實驗數量

各評估項目臨床實驗數量

未完成的臨床實驗

一定期間所採用的被實驗人數

贊助商的各種類的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 顯影劑腎臟病治療藥

有潛力的藥劑

臨床實驗簡介

  • 代表性企業臨床實驗概要
    • General Electric Company
    • Cumberland Pharmaceuticals, Inc.
    • Noorik Biopharmaceuticals AG
    • Ischemix
    • Inotek Pharmaceuticals Corporation
    • Highmark Inc.
    • CorMedix, Inc.
    • CareGroup, Inc.
    • Baxter International Inc.
    • Alberta Innovates- Health Solutions
  • 代表性研究機關/醫院臨床實驗概要
    • Leiden University Medical Center
    • Ospedale Misericordia e Dolce
    • Seoul National University Hospital
    • Tehran University of Medical Sciences
    • 大阪府立急性期綜合醫療中心
    • Qom University of Medical Science and Health Services
    • Shiraz University of Medical Sciences
    • Academic Medical Center
    • Addenbrooke's Hospital
    • Austin Health

5大臨床實驗簡介

附錄

圖表

目錄
Product Code: GDHC2859CTIDB

GlobalData's clinical trial report, "Contrast Induced Nephropathy Global Clinical Trials Review, H2, 2015" provides an overview of Contrast Induced Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Contrast Induced Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Contrast Induced Nephropathy
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Contrast Induced Nephropathy to Genito Urinary System And Sex Hormones Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Contrast Induced Nephropathy to Genito Urinary System And Sex Hormones Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Contrast Induced Nephropathy
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Contrast Induced Nephropathy Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • General Electric Company
      • Clinical Trial Overview of General Electric Company
      • Cumberland Pharmaceuticals, Inc.
      • Clinical Trial Overview of Cumberland Pharmaceuticals, Inc.
      • Noorik Biopharmaceuticals AG
      • Clinical Trial Overview of Noorik Biopharmaceuticals AG
      • Ischemix
      • Clinical Trial Overview of Ischemix
      • Inotek Pharmaceuticals Corporation
      • Clinical Trial Overview of Inotek Pharmaceuticals Corporation
      • Highmark Inc.
      • Clinical Trial Overview of Highmark Inc.
      • CorMedix, Inc.
      • Clinical Trial Overview of CorMedix, Inc.
      • CareGroup, Inc.
      • Clinical Trial Overview of CareGroup, Inc.
      • Baxter International Inc.
      • Clinical Trial Overview of Baxter International Inc.
      • Alberta Innovates- Health Solutions
      • Clinical Trial Overview of Alberta Innovates- Health Solutions
    • Clinical Trial Overview of Top Institutes / Government
      • Leiden University Medical Center
      • Clinical Trial Overview of Leiden University Medical Center
      • Ospedale Misericordia e Dolce
      • Clinical Trial Overview of Ospedale Misericordia e Dolce
      • Seoul National University Hospital
      • Clinical Trial Overview of Seoul National University Hospital
      • Tehran University of Medical Sciences
      • Clinical Trial Overview of Tehran University of Medical Sciences
      • Osaka General Medical Center
      • Clinical Trial Overview of Osaka General Medical Center
      • Qom University of Medical Science and Health Services
      • Clinical Trial Overview of Qom University of Medical Science and Health Services
      • Shiraz University of Medical Sciences
      • Clinical Trial Overview of Shiraz University of Medical Sciences
      • Academic Medical Center
      • Clinical Trial Overview of Academic Medical Center
      • Addenbrooke's Hospital
      • Clinical Trial Overview of Addenbrooke's Hospital
      • Austin Health
      • Clinical Trial Overview of Austin Health
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials by Region, 2015*
  • Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, North America, Top Countries, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Central and South America, Top Countries, 2015*
  • Proportion of Contrast Induced Nephropathy to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2015*
  • Contrast Induced Nephropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Contrast Induced Nephropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Contrast Induced Nephropathy to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2015*
  • Contrast Induced Nephropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Contrast Induced Nephropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials by Phase, 2015*
  • Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials In Progress by Phase 2015*
  • Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Contrast Induced Nephropathy Therapeutics, Global, Withdrawn Clinical Trials, 2015*
  • Contrast Induced Nephropathy Therapeutics, Global, Terminated Clinical Trials, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Contrast Induced Nephropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by General Electric Company, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Cumberland Pharmaceuticals, Inc., 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Noorik Biopharmaceuticals AG, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Ischemix, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Inotek Pharmaceuticals Corporation, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Highmark Inc., 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by CorMedix, Inc., 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by CareGroup, Inc., 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Baxter International Inc., 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Alberta Innovates- Health Solutions, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Ospedale Misericordia e Dolce, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Hospital, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Osaka General Medical Center, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Qom University of Medical Science and Health Services, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Shiraz University of Medical Sciences, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Academic Medical Center, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Addenbrooke's Hospital, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Austin Health, 2015*

List of Figures

  • Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials by Region (%), 2015*
  • Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, North America, Top Countries (%), 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015*
  • Proportion of Contrast Induced Nephropathy to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2015*
  • Contrast Induced Nephropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Contrast Induced Nephropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Contrast Induced Nephropathy to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2015*
  • Contrast Induced Nephropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Contrast Induced Nephropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials by Phase (%), 2015*
  • Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2015*
  • Contrast Induced Nephropathy Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Contrast Induced Nephropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Contrast Induced Nephropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • GlobalData Methodology
Back to Top